These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 28339995)

  • 1. Long-term flecainide therapy in type 3 long QT syndrome.
    Chorin E; Taub R; Medina A; Flint N; Viskin S; Benhorin J
    Europace; 2018 Feb; 20(2):370-376. PubMed ID: 28339995
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Systematic ajmaline challenge in patients with long QT 3 syndrome caused by the most common mutation: a multicentre study.
    Hohmann S; Rudic B; Konrad T; Duncker D; König T; Tülümen E; Rostock T; Borggrefe M; Veltmann C
    Europace; 2017 Oct; 19(10):1723-1729. PubMed ID: 27915266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of flecainide in patients with new SCN5A mutation: mutation-specific therapy for long-QT syndrome?
    Benhorin J; Taub R; Goldmit M; Kerem B; Kass RS; Windman I; Medina A
    Circulation; 2000 Apr; 101(14):1698-706. PubMed ID: 10758053
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lidocaine attenuation testing: An in vivo investigation of putative LQT3-associated variants in the SCN5A-encoded sodium channel.
    Anderson HN; Bos JM; Kapplinger JD; Meskill JM; Ye D; Ackerman MJ
    Heart Rhythm; 2017 Aug; 14(8):1173-1179. PubMed ID: 28412158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ranolazine for Congenital Long-QT Syndrome Type III: Experimental and Long-Term Clinical Data.
    Chorin E; Hu D; Antzelevitch C; Hochstadt A; Belardinelli L; Zeltser D; Barajas-Martinez H; Rozovski U; Rosso R; Adler A; Benhorin J; Viskin S
    Circ Arrhythm Electrophysiol; 2016 Oct; 9(10):. PubMed ID: 27733495
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Normalization of ventricular repolarization with flecainide in long QT syndrome patients with SCN5A:DeltaKPQ mutation.
    Windle JR; Geletka RC; Moss AJ; Zareba W; Atkins DL
    Ann Noninvasive Electrocardiol; 2001 Apr; 6(2):153-8. PubMed ID: 11333173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Further Insights in the Most Common SCN5A Mutation Causing Overlapping Phenotype of Long QT Syndrome, Brugada Syndrome, and Conduction Defect.
    Veltmann C; Barajas-Martinez H; Wolpert C; Borggrefe M; Schimpf R; Pfeiffer R; Cáceres G; Burashnikov E; Antzelevitch C; Hu D
    J Am Heart Assoc; 2016 Jul; 5(7):. PubMed ID: 27381756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Flecainide provocation reveals concealed brugada syndrome in a long QT syndrome family with a novel L1786Q mutation in SCN5A.
    Kanters JK; Yuan L; Hedley PL; Stoevring B; Jons C; Bloch Thomsen PE; Grunnet M; Christiansen M; Jespersen T
    Circ J; 2014; 78(5):1136-43. PubMed ID: 24599044
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The elusive link between LQT3 and Brugada syndrome: the role of flecainide challenge.
    Priori SG; Napolitano C; Schwartz PJ; Bloise R; Crotti L; Ronchetti E
    Circulation; 2000 Aug; 102(9):945-7. PubMed ID: 10961955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gating-dependent mechanisms for flecainide action in SCN5A-linked arrhythmia syndromes.
    Viswanathan PC; Bezzina CR; George AL; Roden DM; Wilde AA; Balser JR
    Circulation; 2001 Sep; 104(10):1200-5. PubMed ID: 11535580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mexiletine rescues a mixed biophysical phenotype of the cardiac sodium channel arising from the SCN5A mutation, N406K, found in LQT3 patients.
    Hu RM; Tester DJ; Li R; Sun T; Peterson BZ; Ackerman MJ; Makielski JC; Tan BH
    Channels (Austin); 2018; 12(1):176-186. PubMed ID: 29983085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A mutation in the sodium channel is responsible for the association of long QT syndrome and familial atrial fibrillation.
    Benito B; Brugada R; Perich RM; Lizotte E; Cinca J; Mont L; Berruezo A; Tolosana JM; Freixa X; Brugada P; Brugada J
    Heart Rhythm; 2008 Oct; 5(10):1434-40. PubMed ID: 18929331
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Specific Therapy Based on the Genotype in a Malignant Form of Long QT3, Carrying the V411M Mutation.
    Blich M; Khoury A; Suleiman M; Lorber A; Gepstein L; Boulous M
    Int Heart J; 2019 Jul; 60(4):979-982. PubMed ID: 31257342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is flecainide dangerous in long QT-3 patients?
    Beinart R; Michailidis A; Gurevitz OT; Glikson M
    Pacing Clin Electrophysiol; 2009 Jan; 32(1):143-5. PubMed ID: 19140927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene-Specific Therapy With Mexiletine Reduces Arrhythmic Events in Patients With Long QT Syndrome Type 3.
    Mazzanti A; Maragna R; Faragli A; Monteforte N; Bloise R; Memmi M; Novelli V; Baiardi P; Bagnardi V; Etheridge SP; Napolitano C; Priori SG
    J Am Coll Cardiol; 2016 Mar; 67(9):1053-1058. PubMed ID: 26940925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mexiletine Shortens the QT Interval in Patients With Potassium Channel-Mediated Type 2 Long QT Syndrome.
    Bos JM; Crotti L; Rohatgi RK; Castelletti S; Dagradi F; Schwartz PJ; Ackerman MJ
    Circ Arrhythm Electrophysiol; 2019 May; 12(5):e007280. PubMed ID: 31006312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A distinct molecular mechanism by which phenytoin rescues a novel long QT 3 variant.
    Gando I; Campana C; Tan RB; Cecchin F; Sobie EA; Coetzee WA
    J Mol Cell Cardiol; 2020 Jul; 144():1-11. PubMed ID: 32339567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene.
    Carrasco JI; Izquierdo I; Medina P; Arnau MÁ; Salvador A; Zorio E
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1058-9. PubMed ID: 22721569
    [No Abstract]   [Full Text] [Related]  

  • 19. SCN5A mutations associated with overlap phenotype of long QT syndrome type 3 and Brugada syndrome.
    Nakaya H
    Circ J; 2014; 78(5):1061-2. PubMed ID: 24694743
    [No Abstract]   [Full Text] [Related]  

  • 20. Cardiac sodium channel mutation associated with epinephrine-induced QT prolongation and sinus node dysfunction.
    Chen J; Makiyama T; Wuriyanghai Y; Ohno S; Sasaki K; Hayano M; Harita T; Nishiuchi S; Yuta Yamamoto ; Ueyama T; Shimizu A; Horie M; Kimura T
    Heart Rhythm; 2016 Jan; 13(1):289-98. PubMed ID: 26282245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.